



Supporting Literature for the Development of the Memantine/Namenda Treatment Protocol for Autism Spectrum Disorder (Glutamatergic Subtype)

1. American Academy of Child and Adolescent Psychiatry (AACAP). (2014). *Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder*. *Journal of the American Academy of Child & Adolescent Psychiatry*, 53(2), 237–257.
<https://doi.org/10.1016/j.jaac.2013.10.013>
2. Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., Hsu, H. A., Trugman, J. M., Palmer, R. H., Graham, S. M., Gage, A. T., Perhach, J. L., & Katz, E. (2017). Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension. *Journal of child and adolescent psychopharmacology*, 27(5), 403–412.
<https://doi.org/10.1089/cap.2015.0146>
3. Häge, A., Banaschewski, T., Buitelaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., Mechler, K., Williams, S. C., Dittmann, R. W., & TACTICS Consortium (2016). Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomized controlled trial. *Trials*, 17(1), 141. <https://doi.org/10.1186/s13063-016-1266-8>
4. Brignell, A., Marraffa, C., Williams, K., & May, T. (2022). Memantine for autism spectrum disorder. *The Cochrane database of systematic reviews*, 8(8), CD013845.
<https://doi.org/10.1002/14651858.CD013845.pub2>
5. Iffland, M., Livingstone, N., Jorgensen, M., Hazell, P., & Gillies, D. (2023). Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). *The Cochrane database of systematic reviews*, 10(10), CD011769. <https://doi.org/10.1002/14651858.CD011769.pub2>
6. Karahmadi, M., Tarrahi, M. J., Vatankhah Ardestani, S. S., Omranifard, V., & Farzaneh, B. (2018). Efficacy of Memantine as Adjunct Therapy for Autism Spectrum Disorder in Children Aged <14 Years. *Advanced biomedical research*, 7, 131. https://doi.org/10.4103/abr.abr_100_18
7. Hardan, A. Y., Hendren, R. L., Aman, M. G., Robb, A., Melmed, R. D., Andersen, K. A., Luchini, R., Rahman, R., Ali, S., Jia, X. D., Mallick, M., Lateiner, J. E., Palmer, R. H., & Graham, S. M. (2019). Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. *Autism : the international journal of research and practice*, 23(8), 2096–2111.
<https://doi.org/10.1177/1362361318824103>
8. Ghaleiha, A., Asadabadi, M., Mohammadi, M. R., Shahei, M., Tabrizi, M., Hajiaghaee, R., Hassanzadeh, E., & Akhondzadeh, S. (2013). Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. *The international journal of neuropsychopharmacology*, 16(4), 783–789. <https://doi.org/10.1017/S1461145712000880>
9. Uzunova, G., Hollander, E., & Shepherd, J. (2014). The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. *Current neuropharmacology*, 12(1), 71–98. <https://doi.org/10.2174/1570159X113116660046>
10. Dessus-Gilbert, M. L., Nourredine, M., Zimmer, L., Rolland, B., Geoffray, M. M., Auffret, M., & Jurek, L. (2024). NMDA antagonist agents for the treatment of symptoms in autism spectrum disorder: a systematic review and meta-analysis. *Frontiers in pharmacology*, 15, 1395867.
<https://doi.org/10.3389/fphar.2024.1395867>



11. Wei, H., Dobkin, C., Sheikh, A. M., Malik, M., Brown, W. T., & Li, X. (2012). The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. *PloS one*, 7(5), e36981. <https://doi.org/10.1371/journal.pone.0036981>
12. Joshi, G., Gönenc, A., DiSalvo, M., Faraone, S. V., Ceranoglu, T. A., Yule, A. M., Uchida, M., McDougale, C. J., & Wozniak, J. (2025). Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial. *JAMA network open*, 8(10), e2534927. <https://doi.org/10.1001/jamanetworkopen.2025.34927>
13. Nair, N., Hegarty, J. P., 2nd, Cirstea, C. M., Gu, M., Appling, C. B., & Beversdorf, D. Q. (2022). Relationship Between MR Spectroscopy-Detected Glutamatergic Neurometabolites and Changes in Social Behaviors in a Pilot Open-Label Trial of Memantine for Adults With Autism Spectrum Disorder. *Frontiers in psychiatry*, 13, 898006. <https://doi.org/10.3389/fpsy.2022.898006>